Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a note issued to investors on Saturday. The firm set a “sell” rating on the stock.

Syros Pharmaceuticals Stock Down 10.9 %

Syros Pharmaceuticals stock opened at $0.03 on Friday. Syros Pharmaceuticals has a 12 month low of $0.02 and a 12 month high of $6.93. The stock has a market cap of $727,147.20, a price-to-earnings ratio of -0.01 and a beta of 1.31. The business has a 50 day moving average price of $0.14 and a two-hundred day moving average price of $0.79.

Institutional Investors Weigh In On Syros Pharmaceuticals

A hedge fund recently bought a new stake in Syros Pharmaceuticals stock. Two Sigma Securities LLC bought a new position in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 107,742 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned approximately 0.40% of Syros Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.